Evidence map›Paper›PMID 33530144›Full record

ReviewCardio-oncology (London, England)2016

Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic.

Sergio Barros-Gomes, Joerg Herrmann, Sharon L Mulvagh, Amir Lerman, Grace Lin, Hector R Villarraga

Open access · goldAbstract readReview
In one paragraph

Review in Cardio-oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 52 citations in OpenAlex.

  1. The Current Cardio-Oncology Landscape Across Australia.Current treatment options in oncology · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. The Role of Nursing in the Delivery of Cardio-Oncology.Current treatment options in oncology · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Practical Approaches to Build and Sustain a Cardio-Oncology Clinic.Journal of cardiovascular development and disease · 2022
    Review
  14. Article
  15. Establishing an Ehlers-Danlos Syndrome Clinic: Lessons Learned.SN comprehensive clinical medicine · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sergio Barros-GomesMayo Clinic, Department of Cardiovascular Diseases, 200 First Street SW, Rochester, MN, 55905, USA.
Joerg HerrmannMayo Clinic, Department of Cardiovascular Diseases, 200 First Street SW, Rochester, MN, 55905, USA.
Sharon L MulvaghMayo Clinic, Department of Cardiovascular Diseases, 200 First Street SW, Rochester, MN, 55905, USA.
Amir LermanMayo Clinic, Department of Cardiovascular Diseases, 200 First Street SW, Rochester, MN, 55905, USA.
Grace LinMayo Clinic, Department of Cardiovascular Diseases, 200 First Street SW, Rochester, MN, 55905, USA.
Hector R VillarragaMayo Clinic, Department of Cardiovascular Diseases, 200 First Street SW, Rochester, MN, 55905, USA. villarraga.hector@mayo.edu.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe diagnosis and management of cardiovascular complications have become a clinical concern for oncologists, cardiologists, surgeons, interventional radiologists, radiation therapy physicians, internists, nurses, pharmacists, administrators, and all the stakeholders involved in the care of cancer patients. Anticancer therapies have extended the lives of patients with cancer, but for some this benefit is attenuated by adverse cardiovascular effects.

methodsThis review article aims to provide an overview of the rationale of setting up a cardio-oncology unit and reflect on our own experience establishing this service, and conclude with some fundamental aspects of consideration for evaluation and management of patients with cancer and cardiovascular diseases.

resultsCardiotoxicity can lead to congestive heart failure and cardiac death. In fact, chemotherapy-related cardiac dysfunction may carry one of the worst prognoses of all types of cardiomyopathies, and has a profound impact on morbidity and mortality in oncology patients. Other complex clinical situations involve cancer patients who might benefit from a highly curative drug in terms of cancer survival but face limitations of its administration because of concomitant cardiovascular diseases. Indeed, the balance between the benefits and risks of the cancer therapy regimen in the context of the cardiovascular status of the individual patient can sometimes be extraordinarily challenging. A subspecialty with a multidisciplinary integrative approach between oncologists, hematologists, cardiologists, among others has thus emerged to address these issues, termed cardio-oncology. Cardio-oncology addresses the spectrum of prevention, detection, monitoring and treatment of cancer patients with cardiovascular diseases, or at risk for cardiotoxicity, in a multidisciplinary manner. In this field, cardiologists assist oncologists and hematologists with cardiovascular recommendations. This can be mediated through e-consultations or face-to-face evaluations.

conclusionCardio-oncology is a subspecialty that assists in the overall care of cancer patients with and without cardiovascular disease in an interdisciplinary fashion. We believe that this partnership of sharing responsibilities and experiences among health-care team members can potentially decrease cancer therapeutics-related cardiovascular complications and improve clinical outcomes.

Indexed as

Cardio-oncologyCardio-oncology programCardiotoxicityCardiovascular risk factorsElectronic medical recordsMultidisciplinary

Identifiers

PMID33530144
PMCPMC7837147
OpenAlexW2336891733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.